Abstract: A DNA aptamer, a pharmaceutical composition comprising the above DNA aptamer, a method for inhibiting the catalytic ability of TXNDC5 and a method for preventing or treating organ fibrosis are revealed. The DNA aptamer comprises a polynucleotide specifically binding to TXNDC5, the polynucleotide is selected from the group consisting of the nucleotide sequence of any one of SEQ ID NOS: 1-14. The pharmaceutical composition comprises the above DNA aptamers as an active ingredient. The method for inhibiting the catalytic ability of TXNDC5 comprises binding the above aptamers to TXNDC5. The method for preventing or treating organ fibrosis comprises administering an effective amount of the above aptamers to a subject.

Abstract: A DNA aptamer, a pharmaceutical composition comprising the above DNA aptamer, a method for inhibiting the catalytic ability of TXNDC5 and a method for preventing or treating organ fibrosis are revealed. The DNA aptamer comprises a polynucleotide specifically binding to TXNDC5, the polynucleotide is selected from the group consisting of the nucleotide sequence of any one of SEQ ID NOS: 1-14. The pharmaceutical composition comprises the above DNA aptamers as an active ingredient. The method for inhibiting the catalytic ability of TXNDC5 comprises binding the above aptamers to TXNDC5. The method for preventing or treating organ fibrosis comprises administering an effective amount of the above aptamers to a subject.

Abstract: A multi-channel real-time cardiovascular performance evaluation system, includes: a multi-channel ECG signals measurement unit, a multi-channel ECG signals processing device, and an ECG signals reconstruction unit. The method uses a MAMA-END algorithm, to mark ECG signals to replace the original ECG signal, and to extract characteristic peak value of the ECG signal. As such, the method is able to extract and reconstruct a first signal having QRS wave, and a second signal having T wave; then the method detects and marks the start of Q wave and the end of T wave on the first signal and the second signal. Therefore, the method is able to determine and evaluate if a patient does have cardiovascular disease, and to locate the lesion positions of a patient having cardiovascular disease.

Abstract: A multi-channel real-time cardiovascular performance evaluation system, includes: a multi-channel ECG signals measurement unit, a multi-channel ECG signals processing device, and an ECG signals reconstruction unit. The method uses a MAMA-END algorithm, to mark ECG signals to replace the original ECG signal, and to extract characteristic peak value of the ECG signal. As such, the method is able to extract and reconstruct a first signal having QRS wave, and a second signal having T wave; then the method detects and marks the start of Q wave and the end of T wave on the first signal and the second signal. Therefore, the method is able to determine and evaluate if a patient does have cardiovascular disease, and to locate the lesion positions of a patient having cardiovascular disease.

Abstract: The present invention discloses a method for prognosing and reducing cardiovascular diseases in patients with kidney diseases, comprising obtaining a bio-sample of a healthy person and a bio-sample of a patient with kidney disease, detecting the expression of specific lncRNA biomarkers individually, such as one or more combinations of DKFZP434I0714, KCNJ2AS1, LOC256880, LOC644656, FAM86FP, FAM66D, LOC100289511, and HTR7P1, comparing the expressions between the samples of the healthy persons and the samples of the patients with kidney diseases to obtain a ratio, and prognosing whether the patients with kidney diseases belong to a high-risk group to have cardiovascular diseases based on the ratio. Furthermore, the method reduces the possibility of patients with kidney diseases to have cardiovascular diseases through the inhibition technology.

Abstract: A method for early diagnosis and treatment of acute coronary syndrome (ACS) in a subject, which measures a level of at least one specific circulating biomarker using immunomagnetic reduction, e.g. FABP4, in the subject within a certain time period after onset of at least one symptom of ACS and administers guideline recommended therapies including early reperfusion therapy and effective drugs to the subject who is observed to have significant dynamic changes in the level of the at least one specific biomarker.

Abstract: A method for prognosing adverse cardiovascular events or deaths in patients with coronary artery diseases, includes the steps of selecting at least one target long non-coding RNA from the group comprising lnc-CXXC11-1:2, lnc-CCT7-1:1, LINC00930:1, TSC22D1-AS1:3, lnc-MEGF10-6:1, lnc-INA-1:1, HPN-AS1:2, lnc-TFAP4-3:1, lnc-SCN8A-2:2, lnc-NCF1-1, BRE-AS1, lnc-ZFAT-6, lnc-SLC46A3-5, lnc-CXCL3-2, lnc-AL137798.1-8, lnc-BCL2L2-PABPN1-1, and lnc-EBF3-4, analyzing the at least one target long non-coding RNA in a sample from a patients with coronary artery diseases, and utilizing the expression as a predictor for adverse cardiovascular events or deaths in patients with coronary artery diseases.

Abstract: Disclosed herein are methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of Physalin to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, Physalin is applied as a coating on an implantable device, such as a stent or a catheter.